Active substance
Lisdexamfetamine
- US FDA 25
- Health Canada 66
- US price lines 13
- NHS prices 6
- Safety 4
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VYVANSE | 30MG; 50MG; 70MG; 20MG; 40MG; 60MG; 10MG | capsule · oral | TAKEDA PHARMS USA | Prescription | 23 Feb 2007 |
| VYVANSE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | TAKEDA PHARMS USA | Prescription | 28 Jan 2017 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | ACTAVIS ELIZABETH | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 20MG; 30MG; 40MG; 50MG; 60MG; 70MG; 10MG | capsule · oral | HIKMA PHARMS | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | AMNEAL | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | MYLAN | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | SPECGX LLC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | SUN PHARM INDS INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | SUN PHARM INDS INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | NORWICH | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | RHODES PHARMS | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | TEVA PHARMS | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | LANNETT CO INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | PRINSTON INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | APOTEX | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | ASCENT PHARMS INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | ALKEM LABS LTD | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | ASCENT PHARMS INC | Prescription | 25 Aug 2023 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | MSN | Prescription | 2 Feb 2024 |
| LISDEXAMFETAMINE DIMESYLATE | 20MG; 30MG; 40MG; 50MG; 60MG; 70MG; 10MG | capsule · oral | SANDOZ | Prescription | 26 Jul 2024 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | ELITE LABS INC | Prescription | 15 Nov 2024 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | GRANULES | Prescription | 16 Dec 2024 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG | tablet, chewable · oral | SPECGX LLC | Prescription | 17 Dec 2024 |
| LISDEXAMFETAMINE DIMESYLATE | 10MG; 20MG; 30MG; 40MG; 50MG; 60MG; 70MG | capsule · oral | GRANULES | Prescription | 29 Jan 2025 |
| ARYNTA | 10MG/ML | solution · oral | AZURITY | Prescription | 16 Jun 2025 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AG-LISDEXAMFETAMINE | 02537567 | 10 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-LISDEXAMFETAMINE | 02537575 | 20 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-LISDEXAMFETAMINE | 02537583 | 30 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-LISDEXAMFETAMINE | 02537591 | 40 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-LISDEXAMFETAMINE | 02537605 | 50 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| AG-LISDEXAMFETAMINE | 02537613 | 60 MG | CAPSULE · ORAL | ANGITA PHARMA INC. |
| APO-LISDEXAMFETAMINE CAPSULES | 02546647 | 10 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546655 | 20 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546663 | 30 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546671 | 40 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546698 | 50 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546701 | 60 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CAPSULES | 02546728 | 70 MG | CAPSULE · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534444 | 10 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534452 | 20 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534460 | 30 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534479 | 40 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534487 | 50 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| APO-LISDEXAMFETAMINE CHEWABLE TABLETS | 02534495 | 60 MG | TABLET (CHEWABLE) · ORAL | APOTEX INC |
| JAMP LISDEXAMFETAMINE | 02535122 | 10 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP LISDEXAMFETAMINE | 02535130 | 20 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP LISDEXAMFETAMINE | 02535149 | 30 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP LISDEXAMFETAMINE | 02535157 | 40 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP LISDEXAMFETAMINE | 02535165 | 50 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
| JAMP LISDEXAMFETAMINE | 02535173 | 60 MG | CAPSULE · ORAL | JAMP PHARMA CORPORATION |
41 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LISDEXAMFETAMINE 10 MG CAPSULE | $2.624 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 10 MG TB CHEW | $3.73818 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 20 MG CAPSULE | $2.43711 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 20 MG TB CHEW | $4.33791 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 30 MG CAPSULE | $2.70088 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 30 MG TB CHEW | $3.29147 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 40 MG CAPSULE | $2.60126 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 40 MG TB CHEW | $3.98071 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 50 MG CAPSULE | $2.63983 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 50 MG TB CHEW | $3.64862 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 60 MG CAPSULE | $2.67291 | per EA | 23 Sep 2026 |
| US NADAC | LISDEXAMFETAMINE 60 MG TB CHEW | $3.64601 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Lisdexamfetamine 20mg capsules | £54.62 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lisdexamfetamine 30mg capsules | £58.24 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lisdexamfetamine 40mg capsules | £62.82 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lisdexamfetamine 50mg capsules | £68.60 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lisdexamfetamine 60mg capsules | £75.18 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Lisdexamfetamine 70mg capsules | £83.16 | 28 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 23 Apr 2026 VYVANSE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 23 Apr 2026 VYVANSE — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - EMA PRAC 9 Jul 2020 PRAC signal: QT prolongation and cardiac arrhythmia
Action for MAH: update of the product information: Yes - EMA PRAC 13 Feb 2020 PRAC signal: QT prolongation and cardiac arrhythmia
Action for MAH: update of the product information: No
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.